Allergan Beats Estimates, Sodastream Results Mixed

Allergan

Allergan and SodaStream released their third quarter earnings reports before opening bell this morning. Allergan posted earnings of $3.48 per share, a 65% year over year increase, and $4.1 billion in revenue, a 90% increase year over year, compared to the analyst estimates of $3.18 per share and $4.03 billion in revenue.

SodaStream reported adjusted earnings of 22 cents per share, which was in line with the consensus estimate, on $110 million in revenue, which slightly missed the expectation of $111.74 million in revenue. In last year’s third quarter, the beverage machine maker posted adjusted earnings of 45 cents per share and revenue of $125.9 million. In constant currency, revenue amounted to $126 million.

Allergan prepares to divest generics business

Allergan’s adjusted EBITDA from continuing operations rose 168% to $2 billion, while adjusted EBIT from continuing operations amounted to $1.93 billion. GAAP losses were $2.35 per share, compared to last year’s losses of $4.40 per share. The Botox maker listed its generics business as discontinued operations as the segment is being held for sale. The divesture of the business to Teva Pharmaceuticals is on track to be completed in the first quarter of 2016.

Allergan’s U.S. Brands saw a 50% increase in net revenue to $2.4 billion, with most of that growth related to the acquisition of legacy products like Botox. Net revenue in the U.S. Medical Aesthetics business was $457 million, while the International Brands business saw revenue climb to $661 million compared to last year’s $58 million. Net revenue for the Anda Distribution business rose 15% to $576 million.

Shares of Allergan rose by as much as 1.25% to $313.67 per share in premarket trades.

SodaStream’s sales fall

SodaStream reported adjusted EBITDA of $9.7 million, compared to last year’s $13.7 million. In constant currency, the metric came in at $14.8 million. The company took $2.5 million in pretax charges in connection with activities related to discontinued products.

In Western Europe, SodaStream’s sales declined from $74.6 million to $68.5 million, while sales in The Americas declined from $29.5 million to $26.2 million. Central and Eastern Europe, Middle East, and Africa sales fell from $8.5 million to $6.3 million, while Asia-Pacific region fell from $13.3 million to $9 million.

As of this writing, shares of SodaStream were up 1.46% at $15.80 per share in premarket trading.

For exclusive info on hedge funds and the latest news from value investing world at only a few dollars a month check out ValueWalk Premium right here.

Multiple people interested? Check out our new corporate plan right here (We are currently offering a major discount)



About the Author

Michelle Jones
Michelle Jones was a television news producer for eight years. She produced the morning news programs for the NBC affiliates in Evansville, Indiana and Huntsville, Alabama and spent a short time at the CBS affiliate in Huntsville. She has experience as a writer and public relations expert for a wide variety of businesses. Michelle has been with ValueWalk since 2012 and is now our editor-in-chief. Email her at Mjones@valuewalk.com.

Be the first to comment on "Allergan Beats Estimates, Sodastream Results Mixed"

Leave a comment

Your email address will not be published.